PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
5.02%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 0.87%. Joel Greenblatt would investigate if growth quality matches quantity.
5.84%
Cost growth exceeding 1.5x Medical - Pharmaceuticals median of 0.71%. Jim Chanos would check for structural cost disadvantages.
1.81%
Growth of 1.81% versus flat Medical - Pharmaceuticals gross profit. Walter Schloss would verify quality.
-3.06%
Margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.03%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
0.69%
Operating expenses growth 50-90% of Medical - Pharmaceuticals median of 1.34%. Mohnish Pabrai would examine discipline.
4.95%
Total costs growth exceeding 1.5x Medical - Pharmaceuticals median of 2.13%. Jim Chanos would check for waste.
No Data
No Data available this quarter, please select a different quarter.
-19.59%
D&A reduction while Medical - Pharmaceuticals median is 5.29%. Seth Klarman would investigate efficiency.
2.53%
EBITDA growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
-2.37%
EBITDA margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
6.86%
Operating income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
1.75%
Margin change of 1.75% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-31.30%
Other expenses reduction while Medical - Pharmaceuticals median is 14.36%. Seth Klarman would investigate advantages.
2.14%
Pre-tax income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
-2.75%
Pre-tax margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
2.39%
Tax expense change of 2.39% versus flat Medical - Pharmaceuticals. Walter Schloss would verify strategy.
1.99%
Net income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
-2.89%
Net margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
2.00%
EPS growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
2.00%
Diluted EPS growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.